Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events

Tomokazu Seki, Kosuke Baba, Tomohiro Hayashi, Risako Furuta, Hiroaki Hirosawa, Taichi Mitsui, Hiroki Maesaka, Syuhei Takasawa, Toshiro Miwa, Keiko Tanaka, Yuji Nakatsuji

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

A 68-year-old man with small-cell lung cancer developed anti-collapsin response-mediator protein (CRMP)-5 antibody-related paraneoplastic neurological syndrome (PNS) presenting with ataxia and chorea during treatment with durvalumab. As a result of steroid therapy, anti-CRMP-5 antibodies became negative, hyperintense lesions on brain magnetic resonance imaging disappeared, and neurological symptoms improved. After resuming durvalumab, he became unable to walk due to neurological adverse events (nAEs). There have been no reported cases manifesting PNSs and nAEs as a result of the same immune checkpoint inhibitors (ICIs) administered at different times. Resuming ICIs in patients diagnosed with PNSs should be performed with prudence.

Original languageEnglish
Pages (from-to)1009-1014
Number of pages6
JournalInternal Medicine
Volume63
Issue number7
DOIs
StatePublished - 2024/03

Keywords

  • anti-CRMP-5 antibody
  • durvalumab
  • immune checkpoint inhibitors
  • immune-related adverse events
  • neurological adverse events
  • paraneoplastic neurological syndromes

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events'. Together they form a unique fingerprint.

Cite this